Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yannick Allanore

Showing results (391-400 of 448) with videos related to

Pageof 45
Sort By:
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Journal of Rheumatology|March 17, 2012
Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosisBaptiste Coustet, Matthieu Bouaziz, Philippe Dieudé, et al.
Arthritis and Rheumatism|August 29, 2013
A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosisEugénie Koumakis, Matthieu Bouaziz, Philippe Dieudé, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|October 11, 2024
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Lancet. Rheumatology|April 18, 2026
Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association studyInmaculada Rodriguez-Martin, Martin Kerick, Carlos Rangel-Peláez, et al.
Rheumatology (Oxford, England)|April 11, 2026
Novel pleiotropic loci links vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenonCarlos Rangel-Peláez, Inmaculada Rodriguez-Martin, Carlos Rosa-Baez, et al.
Arthritis Research & Therapy|February 22, 2012
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research groupChingching Foocharoen, Alan Tyndall, Eric Hachulla, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Pageof 45

Showing results (391-400 of 448) with videos related to

Sort By:
Pageof 45
Arthritis Care & Research|January 26, 2016
The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic SclerosisDinesh Khanna, Veronica J Berrocal, Edward H Giannini, et al.
Annals of the Rheumatic Diseases|January 28, 2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Journal of Rheumatology|March 17, 2012
Independent replication and meta analysis of association studies establish TNFSF4 as a susceptibility gene preferentially associated with the subset of anticentromere-positive patients with systemic sclerosisBaptiste Coustet, Matthieu Bouaziz, Philippe Dieudé, et al.
Arthritis and Rheumatism|August 29, 2013
A regulatory variant in CCR6 is associated with susceptibility to antitopoisomerase-positive systemic sclerosisEugénie Koumakis, Matthieu Bouaziz, Philippe Dieudé, et al.
The Lancet. Rheumatology|January 22, 2024
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trialOliver Distler, Yannick Allanore, Christopher P Denton, et al.
Annals of the Rheumatic Diseases|October 11, 2024
EULAR recommendations for the treatment of systemic sclerosis: 2023 updateFrancesco Del Galdo, Alain Lescoat, Philip G Conaghan, et al.
The Lancet. Rheumatology|April 18, 2026
Sex-specific autosomal susceptibility loci in systemic sclerosis: a genome-wide association studyInmaculada Rodriguez-Martin, Martin Kerick, Carlos Rangel-Peláez, et al.
Rheumatology (Oxford, England)|April 11, 2026
Novel pleiotropic loci links vascular and immune pathways in systemic sclerosis and primary Raynaud's phenomenonCarlos Rangel-Peláez, Inmaculada Rodriguez-Martin, Carlos Rosa-Baez, et al.
Arthritis Research & Therapy|February 22, 2012
Erectile dysfunction is frequent in systemic sclerosis and associated with severe disease: a study of the EULAR Scleroderma Trial and Research groupChingching Foocharoen, Alan Tyndall, Eric Hachulla, et al.
Annals of the Rheumatic Diseases|April 18, 2020
Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trialDinesh Khanna, Yannick Allanore, Christopher P Denton, et al.
Pageof 45